Simvastatin (MK 733)

Simvastatin is a competitive inhibitor of HMG-CoA reductase. This compound has been shown to modulate purified bovine pituitary 20 S proteasome via mild stimulation of chymotrypsin-like activity and inhibition of peptidylglutamylpeptide hydrolyzing activity. Simvastatin is marketed under the trade name Zocor™ and is often prescribed in combination with ezetimibe to treat dyslipidemia. This drug combination is known commercially as Vytorin or Inegy.

Properties:

Appearance & Physical State: white to off- white crystalline powder

Density: 1.11 g/cm3

Boiling Point: 564.9ºC at 760 mmHg

Melting Point: 139ºC

Flash Point: 184.8ºC

Refractive Index: 1.53

HMG-CoA Reductase Inhibitors Related Prodcuts:

Rosuvastatin calcium; Lovastatin; Pitavastatin Calcium; Simvastatin ammonium salt; Rosuvastatin; Rosuvastatin Sodium; Rosuvastatin ethyl ester; Pitavastatin; Pravastatin Sodium

[1]. Slater, E.E., et al. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs, 1988. 36 Suppl 3: p. 72-82.

[2]. Kureishi, Y., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med, 2000. 6(9): p. 1004-10.

[3]. Leung BP, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003 Feb 1;170(3):1524-30.